These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37537015)

  • 21. Trastuzumab deruxtecan
    Zhu Y; Liu K; Zhu X; Qin Q; Zhu H
    Front Pharmacol; 2022; 13():1025243. PubMed ID: 36386213
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.
    Dong L; Lin S; Zhong L; Nian D; Li Y; Wang R; Zhou W; Weng X; Xu X
    Clin Breast Cancer; 2022 Jan; 22(1):e21-e29. PubMed ID: 34238670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 24. Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective.
    Ioannou SS; Marcou Y; Kakouri E; Talias MA
    Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32560485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
    Lang HC; Chen HW; Chiou TJ; Chan AL
    J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer.
    Konishi T; Fujiogi M; Michihata N; Ohbe H; Matsui H; Fushimi K; Tanabe M; Seto Y; Yasunaga H
    Jpn J Clin Oncol; 2022 Oct; 52(10):1115-1123. PubMed ID: 35775313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
    Nguyen AQ; Tran OTM; Nguyen PK; Nguyen HT
    PLoS One; 2024; 19(3):e0300474. PubMed ID: 38489305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
    Cheng LJ; Loke L; Lim EH; Pearce F; Aziz MIA; Ng K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):449-456. PubMed ID: 33595372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.
    Hu S; Wu Y; Luan J; Wang S; Fan G
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17933-17942. PubMed ID: 37964082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
    Diaby V; Adunlin G; Ali AA; Zeichner SB; de Lima Lopes G; Kohn CG; Montero AJ
    Breast Cancer Res Treat; 2016 Nov; 160(1):187-196. PubMed ID: 27654970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
    Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
    Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials.
    Ma R; Shi Y; Yan R; Yin S; Bu H; Huang J
    Crit Rev Oncol Hematol; 2024 Apr; 196():104305. PubMed ID: 38442809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
    J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
    Guarneri V; Passos Coelho JL; Duhoux FP; Egle D; García-Sáenz JÁ; Penault-Llorca F; Selander K; Wildiers H; Zaman K; Laeis P; Lucerna M; Pierga JY
    Future Oncol; 2024; 20(18):1237-1250. PubMed ID: 38592002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore.
    Lim EH; Lim A; Khara JS; Cheong J; Fong J; Sivanesan S; Griffiths M; New E; Lee SC
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):413-426. PubMed ID: 38289042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
    Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
    Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
    Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
    N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.